Current Portfolio

 

ProductMarketerMarketerCreditRating(1)IndicationApproved/ In DevelopmentProductSales RankforMarketerProductTherapeuticRanking2016 SalesRating(2)RoyaltySeller
               
Approved
             
Atripla/Truvada/
Emtriva/Complera/Stribild/Genvoya/Descovy/Odefsey (3)
more info
   A3
A+/A2
AA-/Aa3
HIV/AIDS #2 #1 $11,856
Emory
               
Cimzia
more info
-- Rheumatoid Arthritis (RA), Crohn's #1 #3 $1,446 Nektar Therapeutics
               
Conbriza/Viviant/Aprela/Bazodoxifene (4)
more info
AA/A1 2nd gen. SERM: Osteoporosis -- -- $145 Ligand
               
Cubicin
more info
   AA-/Aa3
AA
AA-/AA2
cSSSI, Bacteremia, Endocarditis -- #2 $1,087 --
               
Galvus/Eucreas
more info
AA Diabetes -- #3 $1,193 Astellas
               
Humira
more info
AA/A1 Rheumatoid Arthritis (RA), UC,
Crohn´s, PsA, AS, Psoriasis
#1 #1 $16,078 AstraZeneca
               
Imbruvica
more info
 AbbVie logo bw AAA/Aaa
--
Mantle Cell Lymphoma (MCL) #2 #1 $2,218 Quest Diagnostics
               
Januvia/Janumet
more info
AA-/Aa3 Diabetes #1 #1 $6,109 Astellas
               
Kalydeco
more info
-- Cystic Fibrosis (CF)  #2  #1 $703 Cystic Fibrosis Foundation
               
Letairis/Volibris
more info
A3/A PAH #3 #1 $985 --
               
Lexiscan
more info
Aa3 Pharmacological Stress Agent for MPI -- #1 $631 --
               
Lyrica
more info
AA/A1 Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Onset Seizures and Fibromyalgia #2 #1 $4,965 Northwestern University
               
Mircera
more info
AA-/A2 Chronic Kidney Disease (CKD) -- #2 $854 Nektar Therapeutics
               
Myozyme/Lumizyme
more info
Sanofi GREY   A-/BBB+ Pompe Disease -- #1 $802 --
               
Nesina
more info
-- Diabetes -- #5 $454 Astellas
               
Onglyza/Kombiglyze
more info
A+/A2 Diabetes -- #4 $777 Astellas
               
Orkambi
more info
-- Cystic Fibrosis (CF) #1  #1 $980 Cystic Fibrosis Foundation
               
Prezista
more info
AAA/Aaa HIV/AIDS -- #1 $1,904 --
               
Priligy
more info
The Menarini Group -- Male Sexual Dysfunction -- -- $42 Forest Laboratories
Furiex Pharmaceuticals
               
Remicade
more info
AAA/Aaa
AA-/Aa3
--
Rheumatoid Arthritis (RA), UC, Crohn´s, PsA, AS, Psoriasis #2 / #1 / #4 #2 / #1 / #1 $8,074 NYU
               
RotaTeq
more info
AA-/Aa3 Rotavirus Vaccine -- #1 $651 CHOP
               
Savella
more info
allergan logo bw Baa3 Fibromyalgia -- #1 $103 --
               
Soliqua/Lyxumia
more info
Sanofi GREY A-/BBB+ Fibromyalgia -- -- -- --
               
Tecfidera
more info
Biogen A- Psoriasis, Multiple Sclerosis #1 #2 $3,968 --
               
Thalomid
more info
Baa2 Multiple Myeloma -- -- $207 --
               
TOBI
more info
AA Anti-Infectives (cystic fibrosis) -- -- $102 --
               
Tradjenta
more info
Ba1 Diabetes -- -- $1,248 Astellas
               
Tysabri
more info
Biogen A- Relapsing forms of multiple sclerosis (MS) #3 #3 $1,964 Perrigo
               
Xtandi
more info
  AA/A1
Aa3
Metastatic castration-resistant prostate cancer (CRPC) #1 / #4 #1 $2,564 UCLA
               
In Development
             
Bosulif
more info
  AA/A1 Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)  -- -- $157 Pfizer
               
Ibrance (Palbociclib)
more info
  AA/A1 estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer  #4 -- $2,135 Pfizer
               
Kalydeco + tezacaftor
more info
  -- Cystic Fibrosis (CF)  -- -- -- Cystic Fibrosis Foundation
               
Kalydeco + tezacaftor + 2nd. generation corrector (VX-440, VX-152, VX-659 or VX-445)
more info
  -- Cystic Fibrosis (CF)  -- -- -- Cystic Fibrosis Foundation
               
               
Expired Royalties
             
Rituxan - RP Royalty Expired Q4 2014
more info
AA-/A2 B-cell Lymphoma, RA,
Multiple Sclerosis, Lupus
#1 #1 $7,410 XOMA
               
Neupogen/Neulasta - RP Royalty Expired Q2 2015
more info
A+/A3 Cancer, white blood cell stimulant #2 #1 $5,556 MSK
               
               
Total $87,368 
       
(1) S&P / Moody's
(2) Sales in $M in territories for which Royalty Pharma receives royalties.
(3) Aggregate end-user sales of all products; Royalty Pharma receives royalties on emtricitabine-related portion.
(4) Approved in select EU countries and Japan.

 

 


© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.